Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of “Buy” by Brokerages

by · The Markets Daily

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have received an average recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $54.20.

TARS has been the subject of a number of recent research reports. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th.

Get Our Latest Stock Analysis on Tarsus Pharmaceuticals

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Cowen AND Company LLC lifted its holdings in Tarsus Pharmaceuticals by 3.5% during the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after purchasing an additional 74,855 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after acquiring an additional 698,712 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Tarsus Pharmaceuticals by 7.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after acquiring an additional 77,825 shares in the last quarter. Ikarian Capital LLC increased its holdings in Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after purchasing an additional 230,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Tarsus Pharmaceuticals by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after purchasing an additional 62,555 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 0.5 %

Shares of Tarsus Pharmaceuticals stock opened at $54.70 on Tuesday. Tarsus Pharmaceuticals has a 1 year low of $18.99 and a 1 year high of $57.14. The company’s fifty day simple moving average is $48.24 and its 200-day simple moving average is $35.82. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -14.36 and a beta of 1.04. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

About Tarsus Pharmaceuticals

(Get Free Report

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Stories